Cargando…

Impact of Idarucizumab and Andexanet Alfa on DOAC Plasma Concentration and ClotPro(®) Clotting Time: An Ex Vivo Spiking Study in A Cohort of Trauma Patients

Specific antagonists have been developed for the reversal of direct oral anticoagulants (DOAC). We investigated the impact of these reversal agents on the plasma concentration and visco-elastic test results of dabigatran and factor Xa inhibitors. After baseline measurements of dabigatran, the plasma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oberladstätter, Daniel, Schlimp, Christoph J., Zipperle, Johannes, Osuchowski, Marcin F., Voelckel, Wolfgang, Grottke, Oliver, Schöchl, Herbert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8396852/ https://www.ncbi.nlm.nih.gov/pubmed/34441771 http://dx.doi.org/10.3390/jcm10163476

Ejemplares similares

High Interleukin-6 Plasma Concentration upon Admission Is Predictive of Massive Transfusion in Severely Injured Patients
por: Weichselbaum, Nadja, et al.
Publicado: (2021)

Conventional and Pro-Inflammatory Pathways of Fibrinolytic Activation in Non-Traumatic Hyperfibrinolysis
por: Zipperle, Johannes, et al.
Publicado: (2022)

Multiplate Platelet Function Testing upon Emergency Room Admission Fails to Provide Useful Information in Major Trauma Patients Not on Platelet Inhibitors
por: Pommer, Peter, et al.
Publicado: (2022)

Operability of a Resonance-Based Viscoelastic Haemostatic Analyzer in the High-Vibration Environment of Air Medical Transport
por: Zipperle, Johannes, et al.
Publicado: (2022)

Factor XIII Measurement and Substitution in Trauma Patients after Admission to an Intensive Care Unit
por: Katzensteiner, Moritz, et al.
Publicado: (2022)

Effect of Dabigatran on Clotting Time in the Clotpro Ecarin Clotting Assay: A Prospective, Single-Arm, Open-Label Study
por: Fong, Alan Yean Yip, et al.
Publicado: (2020)

Monitoring the Coagulation Profile of COVID-19 Patients Using Standard and ClotPro(®) Hemostasis Tests
por: Milić, Dragan, et al.
Publicado: (2023)

Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab
por: Hu, Tiffany Y, et al.
Publicado: (2016)

Impact of fibrinogen concentrate alone or with prothrombin complex concentrate (+/− fresh frozen plasma) on plasma fibrinogen level and fibrin-based clot strength (FIBTEM) in major trauma: a retrospective study
por: Schlimp, Christoph J, et al.
Publicado: (2013)

A comparison of the ClotPro system with rotational thromboelastometry in cardiac surgery: a prospective observational study
por: Yoshii, Ryogo, et al.
Publicado: (2022)

Rapid Detection of Apixaban by a ROTEM-Based Approach and Reversibility with Andexanet Alfa or DOAC-Stop
por: Taune, Viktor, et al.
Publicado: (2022)

Assessing the Methodology for Calculating Platelet Contribution to Clot Strength (Platelet Component) in Thromboelastometry and Thrombelastography
por: Solomon, Cristina, et al.
Publicado: (2015)

Comparison of fibrin-based clot elasticity parameters measured by free oscillation rheometry (ReoRox(®)) versus thromboelastometry (ROTEM(®))
por: Solomon, Cristina, et al.
Publicado: (2015)

Comparison of the New Viscoelastic Coagulation Analyzer ClotPro® With ROTEM® Delta and Conventional Coagulation Tests in Critically Ill Patients With COVID-19
por: Infanger, Lukas, et al.
Publicado: (2021)

Retrospective review of Andexanet Alfa versus 4-Factor Prothrombin Complex Concentrate for reversal of DOAC-Associated Intracranial Hemorrhage
por: Troyer, Camille, et al.
Publicado: (2022)

Costs and Healthcare Resource Utilization Associated with Idarucizumab or Andexanet Alfa Oral Anticoagulant Reversal in Patients Hospitalized with Life-Threatening Bleeds
por: Spyropoulos, Alex C., et al.
Publicado: (2022)

New under the sun: ClotPro's ECA-test detects hyperfibrinolysis in a higher number of patients, more frequently and 9 min earlier
por: Zátroch, István, et al.
Publicado: (2023)

Andexanet Alfa: First Global Approval
por: Heo, Young-A
Publicado: (2018)

Institutional Experience of Using Andexanet Alfa
por: Khadka, Sushmita, et al.
Publicado: (2020)

Correction to: Andexanet Alfa: First Global Approval
por: Heo, Young-A
Publicado: (2018)

To Clot or Not to Clot: Is That the Question?
por: Favaloro, Emmanuel J.
Publicado: (2023)

Predictive ability of viscoelastic testing using ClotPro® for short-term outcome in patients with severe Covid-19 ARDS with or without ECMO therapy: a retrospective study
por: Heubner, Lars, et al.
Publicado: (2022)

Difficult Intraoperative Heparinization Following Andexanet Alfa Administration
por: Watson, C. James, et al.
Publicado: (2019)

Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa
por: Lewis, Joseph, et al.
Publicado: (2022)

Successful use of an antithrombin for heparin resistance with andexanet alfa
por: Honda, Jun, et al.
Publicado: (2023)

Postponing intubation in spontaneously breathing major trauma patients upon emergency room admission does not impair outcome
por: Schwaiger, Philipp, et al.
Publicado: (2019)

Reversing factor Xa inhibitors – clinical utility of andexanet alfa
por: Kaatz, Scott, et al.
Publicado: (2017)

Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation
por: Carpenter, Elise, et al.
Publicado: (2019)

Andexanet-Alfa-Associated Heparin Resistance in the Context of Hemorrhagic Stroke
por: Müther, Michael, et al.
Publicado: (2022)

Andexanet alfa — Recommendations for clinical use. Multidisciplinary experts’ standpoint
por: Kubica, Jacek, et al.
Publicado: (2023)

Clot or Not?
por: Peretz-Larochelle, Maude, et al.
Publicado: (2018)

Efanesoctocog alfa elicits functional clot formation that is indistinguishable to that of recombinant factor VIII
por: Demers, Melanie, et al.
Publicado: (2022)

Endogenous thrombin potential following hemostatic therapy with 4-factor prothrombin complex concentrate: a 7-day observational study of trauma patients
por: Schöchl, Herbert, et al.
Publicado: (2014)

Effect of coagulation factor concentrate administration on ROTEM® parameters in major trauma
por: Ponschab, Martin, et al.
Publicado: (2015)

Antithrombotic therapy in chronic liver disease: to clot or not to clot
por: Calvert, Peter, et al.
Publicado: (2021)

Association of clot ultrastructure with clot perviousness in stroke patients
por: Kim, Young Dae, et al.
Publicado: (2023)

Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures
por: Bradshaw, Paige Garber, et al.
Publicado: (2022)

Successful Nafamostat Mesilate Administration for Andexanet Alfa-Induced Heparin Resistance
por: Kitaura, Atsuhiro, et al.
Publicado: (2023)

Clot. ISR
Publicado: (2016)

Clotting revisited
por: Van Epps, Heather L.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_8k0hdrq41rq6dple2kmb931750